JPML Consolidates Birth Defect Suits Over GSK's Zofran
Law360, New York (October 13, 2015, 9:41 PM EDT) -- The U.S. Judicial Panel on Multidistrict Litigation on Tuesday consolidated in Massachusetts district court a number of lawsuits alleging GlaxoSmithKline’s “off label” promotion of its anti-nausea drug Zofran for morning sickness led to birth defects, saying five similar actions are pending in the court already, including the first-filed complaint.
The MDL panel found that 12 lawsuits, some of which are proposed class actions, warranted consolidation as they all involved common allegations that GlaxoSmithKline’s Zofran and its generic equivalent, Ondansetron, a prescription medication for the treatment of nausea, causes birth birth defects in children when their mothers ingest the drug while pregnant....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!